Lista de obras -

Adding to the checkpoint blockade armamentarium

artículo científico publicado en 2019

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

scientific article published on 15 November 2019

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

article

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

scientific article published on 11 February 2020

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

artículo científico publicado en 2016

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer

artículo científico publicado en 2019

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.

artículo científico publicado en 2017

Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade

scientific article published on 21 September 2020

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

scientific article published on 12 December 2018

Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy

artículo científico publicado en 2020

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

artículo científico publicado en 2020

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

scientific article published on 03 May 2019

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

artículo científico publicado en 2018

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

artículo científico publicado en 2017

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer

artículo científico publicado en 2021

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

artículo científico publicado en 2020

Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child

artículo científico publicado en 2021

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

artículo científico publicado en 2020

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

scientific article published on 27 January 2021

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

artículo científico publicado en 2018

Neoantigen-directed immune escape in lung cancer evolution

artículo científico publicado en 2019

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2019

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

artículo científico publicado en 2018

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

artículo científico publicado en 2019

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade

scientific article published on 14 August 2020

Protein-altering germline mutations implicate novel genes related to lung cancer development

scientific article published on 11 May 2020

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

scientific article published on 24 July 2020

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer

artículo científico publicado en 2019

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

artículo científico publicado en 2019

Use of Circulating Tumor DNA for Cancer Immunotherapy

scientific article published on 08 July 2019

Lista de obras de

Adding to the checkpoint blockade armamentarium

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.

Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Neoantigen-directed immune escape in lung cancer evolution

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade

Protein-altering germline mutations implicate novel genes related to lung cancer development

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Use of Circulating Tumor DNA for Cancer Immunotherapy